Jon CohenScience’s COVID-19 reporting is supported by the Heising-Simons Foundation.The questions are urgent, and the funding is in place.
But a highly anticipated, $130 million clinical trial, meant to test the efficacy of the novel messenger RNA (mRNA) vaccines for COVID-19 against a key variant of the pandemic coronavirus as well as in people living with HIV and pregnant women, is stalled.
It is ready to launch in eight countries in sub-Saharan Africa, yet neither maker of the vaccines, Pfizer and Moderna, wants to participate—or even provide their vaccines.A group of prominent HIV advocates and activists in South Africa has written a letter complaining about the delay to U.S.